亚虹医药：APL-1702国际多中心Ⅲ期临床试验结果获发表

Core Viewpoint - The clinical trial results for APL-1702, a treatment for high-grade squamous intraepithelial lesions (HSIL), have been published in the prestigious journal Med, indicating significant efficacy compared to placebo [1] Group 1: Clinical Trial Results - APL-1702 demonstrated an 89.4% increase in response rate compared to the placebo group, with rates of 41.1% for APL-1702 versus 21.7% for placebo (p=0.0001) [1] - The overall response rate at the 12-month mark reached 44.4%, indicating stable long-term efficacy [1] Group 2: Regulatory Status - APL-1702 is currently under review by the National Medical Products Administration (NMPA) in China, with uncertainty regarding its approval and market launch timeline [1] - The publication of the clinical trial data is not expected to have a significant impact on the company's recent performance [1]